Skip to main content
ANEB
NASDAQ Life Sciences

Anebulo Pharmaceuticals Finalizes Tender Offer, Repurchasing Shares at Significant Premium

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.855
Mkt Cap
$35.123M
52W Low
$0.8
52W High
$3.42
52W Position info
6.8% above low
Off High info
75% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ANEB is trading near its 52-week low of $0.8 (6.8% above the low).

Summary

Anebulo Pharmaceuticals announced the final results of its tender offer, repurchasing 300,000 shares at $3.50 each for a total of $1.05 million, significantly above the current market price.


Key Events · Financing and Capital Events · ANEB

  • Final Tender Offer Results

    Anebulo Pharmaceuticals announced the final results of its tender offer, which expired on January 26, 2026, following preliminary results disclosed on January 27, 2026.

  • Share Repurchase Details

    The company repurchased 300,000 shares of common stock at a price of $3.50 per share, totaling approximately $1.05 million.

  • Significant Premium Paid

    The repurchase price of $3.50 per share represents a substantial premium over the current market price of $0.85.

  • Oversubscribed Offer

    The tender offer was oversubscribed, with 4,907,881 shares tendered, but only 300,000 were accepted on a pro-rata basis (3.47392% proration factor), with odd lots accepted in full.


Analysis · ANEB · Life Sciences

This 8-K provides the final details of Anebulo Pharmaceuticals' tender offer, which was oversubscribed and completed at a substantial premium to the current stock price. The company repurchased 300,000 shares for approximately $1.05 million, representing about 0.73% of outstanding shares. The tender offer price of $3.50 per share is significantly higher than the current market price of $0.85, indicating management's confidence in the company's valuation and a strategic move to reduce shareholder count, particularly for smaller "odd lot" holders. This capital allocation decision, while reducing cash, signals a positive outlook from the company's perspective.

At the time of this filing, ANEB was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.1M. The 52-week trading range was $0.80 to $3.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANEB - Latest Insights

ANEB
Feb 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.4689
Real-time Price: $0.330 info
Change: -$0.1389 (-30%) info
Market Cap: $13.459M info
ANEB
Feb 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4749
Real-time Price: $0.330 info
Change: -$0.1449 (-31%) info
Market Cap: $13.459M info
ANEB
Feb 06, 2026, 9:20 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.4401
Real-time Price: $0.330 info
Change: -$0.1101 (-25%) info
Market Cap: $13.459M info
ANEB
Jan 27, 2026, 9:24 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.08
Real-time Price: $0.330 info
Change: -$0.750 (-69%) info
Market Cap: $13.459M info
ANEB
Jan 08, 2026, 9:21 AM EST
Filing Type: SC TO-I/A
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $0.330 info
Change: -$0.880 (-73%) info
Market Cap: $13.459M info